Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
SEC Accession No. 0001104659-25-040354
Filing Date
2025-04-28
Accepted
2025-04-28 18:43:57
Documents
5

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13D/A  
1 primary_doc.xml SCHEDULE 13D/A 11142
2 EXHIBIT C tm2513373d1_ex99-c.htm EX-99.(C) 18338
3 GRAPHIC tm2513373d1_ex99-cimg01.jpg GRAPHIC 4618
4 GRAPHIC tm2513373d1_ex99-cimg02.jpg GRAPHIC 1128
5 GRAPHIC tm2513373d1_ex99-cimg04.jpg GRAPHIC 5355
  Complete submission text file 0001104659-25-040354.txt   46938
Mailing Address 1050 WALTHAM STREET, SUITE 302 LEXINGTON MA 02421
Business Address 1050 WALTHAM STREET, SUITE 302 LEXINGTON MA 02421 617-314-6297
Keros Therapeutics, Inc. (Subject) CIK: 0001664710 (see all company filings)

EIN.: 811173868 | Fiscal Year End: 1231
Type: SCHEDULE 13D/A | Act: 34 | File No.: 005-91484 | Film No.: 25882090
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address 3503 WILD CHERRY DRIVE BUILDING 9 AUSTIN TX 78738
Business Address 3503 WILD CHERRY DRIVE BUILDING 9 AUSTIN TX 78738 512-254-3790
ADAR1 Capital Management, LLC (Filed by) CIK: 0001940272 (see all company filings)

EIN.: 000000000 | State of Incorp.: TX | Fiscal Year End: 1231
Type: SCHEDULE 13D/A